Drug of Choice for Severe Non-Purulent Cellulitis with Significant Systemic Signs of Infection According to IDSA

Treatment Algorithm for Severe Non-Purulent Cellulitis

The IDSA recommends intravenous vancomycin as the first-line drug of choice for severe non-purulent cellulitis with significant systemic signs of infection, with alternatives including linezolid, daptomycin, or telavancin 1, 2, 3
IV vancomycin is the recommended first-line agent for hospitalized patients with severe non-purulent cellulitis with systemic signs of infection (A-I level evidence) 2, 3
Initial empiric therapy should target beta-hemolytic streptococci, but in severe cases with systemic toxicity, empirical coverage for MRSA should be considered pending culture data 1, 2

Blood cultures should be obtained in patients with severe local infection, signs of systemic illness, or those who have not responded adequately to initial treatment 1

For aggressive infections with signs of systemic toxicity, broader coverage may be necessary 3
Consider combination therapy (e.g., vancomycin plus piperacillin-tazobactam or a carbapenem) if necrotizing infection is suspected 3

Non-purulent cellulitis is primarily caused by beta-hemolytic streptococci, but in severe cases with systemic signs, MRSA coverage is warranted 1, 2
While beta-lactams like cefazolin may be considered for hospitalized patients with non-purulent cellulitis, modification to MRSA-active therapy is recommended if there is no clinical response or if systemic signs are present 2, 3

Failing to obtain appropriate cultures before initiating antibiotics in severe cases 1
Inadequate coverage for MRSA in severe infections with systemic signs 2
Using rifampin as a single agent or as adjunctive therapy for SSTI (not recommended, A-III) 1, 2
Inadequate duration of therapy for severe infections 2